Live Breaking News & Updates on Oramed Pharmaceutical

Stay updated with breaking news from Oramed pharmaceutical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Analysts Expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Will Post Quarterly Sales of $700,000.00

Brokerages expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to announce sales of $700,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $670,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of […] ....

United States , Thomson Reuter , Kevin Rakin , Oramed Pharmaceuticals Inc , Morgan Stanley , Securities Exchange Commission , Zacks Investment Research , Oramed Pharmaceuticals , America Corp , Invesco Ltd , Oramed Pharmaceuticals Get Rating , Wells Fargo Company , Cantor Fitzgerald , Royal Bank , Get Rating , Zacks Investment , Oramed Pharmaceutical , Investment Research , Director Kevin Rakin , Exchange Commission , Wells Fargo , Nasdaq Ormp ,

-$0.19 Earnings Per Share Expected for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) This Quarter

Brokerages predict that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will report earnings of ($0.19) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.23). Oramed Pharmaceuticals reported earnings of ($0.17) per share during […] ....

Oramed Pharmaceuticals Inc , Zacks Investment Research , Oramed Pharmaceuticals , Invesco Ltd , Cantor Fitzgerald , Moors Cabot Inc , Oramed Pharmaceuticals Company Profile Get Rating , Millennium Management , Get Rating , Zacks Investment , Oramed Pharmaceutical , Capital Management , State Street Corp , Pharmaceuticals Company Profile , Nasdaq Ormp ,

$700,000.00 in Sales Expected for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) This Quarter

Wall Street analysts forecast that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will announce $700,000.00 in sales for the current quarter, Zacks reports. Two analysts have provided estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $670,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 4.5%. […] ....

Thomson Reuter , Oramed Pharmaceuticals Inc , Zacks Investment Research , Blackrock Inc , Oramed Pharmaceuticals , Invesco Ltd , Greylin Investment Mangement Inc , Cantor Fitzgerald , Oramed Pharmaceuticals Company Profile Get Rating , Wall Street , Get Rating , Oramed Pharmaceutical , Investment Mangement , Street Corp , Altium Capital Management , Pharmaceuticals Company Profile , Nasdaq Ormp ,

Massive spike in new COVID infections as new vaccine trial rolled out in SA

On Wednesday, 54 COVID-related deaths were reported in the last 24 hours bringing the total number of people who have succumbed to the virus to 90,226.
....

South Africa , Nadav Kidron , National Institute For Communicable Diseases , National Institute , Communicable Diseases , Oramed Pharmaceutical , Chief Executive Officer Nadav Kidron , Covid 19 ,